Belgium’s DRG debate is often framed as a shift toward “case-based payment.” That description is technically correct but strategically misleading. In Belgium, DRGs are not a market-shaping instrument; they are a containment tool. They are deployed selectively, kept deliberately narrow, and designed to make hospital expenditure transparent and controllable in a system that views volume growth as a fiscal risk rather than a sign of efficiency. Nowhere is this logic clearer than in Belgium’s low-variability APR-DRG framework: a case tariff that pays for the medical act while explicitly excluding implants, devices, consumables, and ward costs. That single design choice explains why so many otherwise sophisticated innovators misread how reimbursement actually works in Belgium.
What Belgium actually means when it uses DRGs
Belgium does not treat DRGs as a comprehensive reform of hospital payment. Instead, it uses them selectively, as a precision instrument within a layered financing architecture that has evolved to manage political, clinical, and fiscal risk.
Hospitals continue to be funded through a combination of global budgets, regulated physician fees, supplements, exceptions, and targeted case-based mechanisms. DRGs do not replace this structure. They sit inside it carefully bounded and intentionally incomplete.
The policy logic is straightforward. Where care is predictable, low-risk, and invariant, Belgium is willing to standardise payment and compress variation. Where care is complex, high-cost, or politically sensitive, it is deliberately kept outside DRG logic altogether.
This is why Belgium’s most developed DRG-like mechanism is not a universal system, but the low-variability APR-DRG framework introduced in 2019 and maintained with notable stability under the authority of INAMI-RIZIV. The system applies only to a narrow set of non-complex procedures and has changed little year on year a signal that it is considered functionally complete rather than provisional.
In practical terms, Belgian DRGs are not designed to discover value or encourage uptake. They are designed to define the outer boundary of what the system is prepared to standardise. Everything beyond that boundary implants, advanced devices, rare disease pathways, specialist diagnostics is managed through different mechanisms, often involving authorisation, exception handling, or concentration in specialised centres.
Understanding this distinction is essential. In Belgium, DRGs do not tell you how innovation will be paid. They tell you where innovation is not expected to operate.
How the low-variability APR-DRG system actually works
The low-variability APR-DRG system is best understood not as a reimbursement innovation, but as a boundary-setting device.
Introduced in 2019 and administered by INAMI-RIZIV, the framework applies only to a tightly defined set of routine, non-complex procedures where clinical pathways are stable and resource use is predictable. Today, the system comprises 61 APR-DRG groups, a number that has remained unchanged through successive annual updates, including 2026.
For cases that fall within scope, hospitals receive a fixed tariff per case. But the tariff is deliberately incomplete. It pays only for the medical act the professional component of care delivery and precisely excludes those elements that introduce cost volatility.
Specifically, the APR-DRG tariff does not cover:
- implants,
- medical devices and consumables,
- ward or hotel costs.
This design choice is central. Belgium has drawn a hard line between what can be standardised and what must remain visible to the payer. By excluding implants and devices from the case price, the system prevents technological cost growth from being silently normalised into routine tariffs. Any increase in spend remains explicit, traceable, and contestable.
From a payer perspective, this is not a weakness but a feature. It preserves budgetary control and avoids the long-term ratchet effect seen in DRG systems where successive generations of technology are gradually absorbed into ever-higher case prices.
The stability of the APR-DRG framework reinforces this interpretation. The 2026 update introduced no new groups and only marginal tariff adjustments, averaging around –0.5%. There was no language of expansion, innovation, or reform. In policy terms, that stability is a signal: the system is considered fit for purpose.
What Belgium has built here is not a platform for adoption, but a reference point. The APR-DRG defines the zone in which hospitals are expected to operate efficiently, absorb incremental change, and deliver care within fixed constraints. Outside that zone, different rules apply.
Those rules authorisation, exception handling, and concentration in specialised centres are where complexity and innovation are intentionally managed.
Where implants and expensive devices are actually paid: the reimbursement lists
Excluding implants from DRGs does not mean Belgium leaves hospitals to absorb them blindly. Instead, Belgium manages high-cost devices through explicit reimbursement lists and controlled financing mechanisms, administered centrally by INAMI-RIZIV.
These lists are the other half of the DRG architecture — and they are where market-access work happens for device manufacturers.
In practical terms, Belgium separates hospital financing into two distinct logics:
- DRGs → discipline routine clinical activity
- Device lists and exceptions → control exposure to cost volatility and innovation risk
Implants and expensive devices are therefore handled through:
- named reimbursement lists,
- product-specific inclusion decisions,
- defined indications and usage conditions,
- and, in some cases, volume or centre restrictions.
This preserves payer visibility and allows costs to be debated, adjusted, or withdrawn without reopening DRG tariffs.
What these lists are designed to do
From a payer perspective, the purpose of device and implant lists is not to accelerate adoption. It is to retain optionality.
By listing devices separately, Belgium can:
- approve reimbursement without normalising cost into routine care,
- restrict use to defined patient groups or indications,
- tie reimbursement to authorisation or specialised delivery settings,
- and revise or remove coverage if utilisation or budget impact drifts.
This is fundamentally different from DRG bundling systems, where once a device is “inside the tariff,” it is effectively locked in.
In Belgium, listing is permission to exist, not a guarantee of scale.
How this interacts with Centres of Expertise
In many cases, reimbursement lists are implicitly or explicitly linked to:
- authorised centres,
- specialised care programmes,
- or minimum volume and competency thresholds.
This is how Belgium aligns financial control with service concentration.
High-cost implants are not just paid differently; they are often expected to live in different places. The combination of:
- exclusion from DRGs,
- listing-based reimbursement,
- and authorisation rules
ensures that complex or expensive technologies are delivered where expertise is concentrated and variation is defensible.
The strategic implication for innovators
For companies selling implants or advanced devices into Belgium, the critical mistake is to focus on DRG inclusion.
The correct strategic questions are:
- Is this technology eligible for listing?
- Under what conditions of use?
- In which centres?
- With what constraints on indication or volume?
Belgium does not price devices by embedding them into case tariffs.
It governs them by keeping them separate, visible, and revisable.
That separation is not a barrier.
It is the system doing exactly what it was designed to do.
Why implants and high-cost devices sit outside Belgian DRGs
The exclusion of implants and devices from Belgian DRG tariffs is not a technical anomaly. It is the organising principle of the system.
In most DRG-based models, implants are bundled into the case price on the assumption that competition, procurement pressure, and clinical standardisation will contain costs over time. Belgium has drawn the opposite conclusion. Once high-cost items are embedded in case tariffs, cost inflation becomes structurally invisible and therefore politically and fiscally irreversible.
Belgium’s response has been to separate the predictable from the volatile.
By allowing DRGs to cover only the medical act, the payer retains direct line-of-sight over the elements most likely to drive budget growth: implants, advanced devices, and consumables. These costs remain identifiable, negotiable, and crucially removable if they fail to justify themselves.
From an economic perspective, this design prevents what might be called tariff sedimentation: the gradual accumulation of successive generations of technology into a single, ever-higher case price that no longer reflects current clinical necessity. Belgium has chosen transparency over convenience.
For hospitals, this creates an extremely specific incentive environment. Adoption of a new implant or device does not automatically generate additional reimbursement. Instead, the cost pressure lands where it can be felt in procurement decisions, pathway redesign, and the internal trade-offs required to stay within fixed envelopes. Technologies are adopted not because they can be billed, but because they make delivery workable.
What happens when a new technology enters a DRG pathway
When a new technology is introduced into a pathway governed by an APR-DRG, the default assumption is neither enthusiasm nor rejection. It is absorption.
If the technology:
- reduces length of stay,
- simplifies workflow,
- lowers complication rates,
- or replaces an existing cost,
it may be adopted quietly, without any change to the tariff structure. Its value is realised operationally rather than financially.
If, however, the technology:
- increases cost per case,
- adds procedural steps,
- requires specialist interpretation,
- or expands the eligible patient population,
the DRG framework offers no automatic accommodation. In these cases, adoption tends to stall unless the technology can be routed through a different part of the system typically via authorisation, exception mechanisms, or concentration in specialised centres.
This is why many companies experience Belgium as paradoxical: clinically sophisticated, technically receptive, but commercially inert. The system is not designed to surface marginal value through pricing. It is designed to filter out anything that destabilises predictable delivery.
How to use Belgian DRG logic as a market-access map
For innovators, the practical value of Belgium’s DRG system lies less in the tariff itself than in what the tariff signals.
A useful rule of thumb is this:
- If your technology fits comfortably inside a low-variability DRG, it is expected to be efficient, interchangeable, and absorbable.
- If it does not, Belgium expects it to be contained, not generalised.
DRGs therefore act as a sorting mechanism. They delineate the zone of routine care the part of the system where hospitals are expected to manage cost pressure internally and, by exclusion, point toward the areas where different funding and governance logic applies.
Successful strategies in Belgium start by asking not, “How do we get paid?,” but “Where does the system expect this to live?” The answer to that question determines whether the right interlocutor is a coding office, a procurement committee, or a specialised clinical programme.
The quiet discipline at the heart of the system
Taken together, Belgium’s DRG design reveals a coherent, if understated, philosophy.
Routine care is standardised.
Variation is compressed.
Volume growth is dampened.
Cost drivers remain visible.
Innovation is not rejected but it is never indulged. Technologies that stabilise delivery are tolerated, often without ceremony. Those that add complexity must justify themselves elsewhere, under tighter governance and clearer limits.
That is why Belgian DRGs feel static from the outside. Stability is not a sign of inertia. It is the signal that the boundary has been drawn and is being actively defended.
References
Belgian Health Care Knowledge Center (KCE) (2024) Expenditure control measures in DRG-based hospital payment systems per admission. KCE Report 392. Brussels: KCE. Available at: https://kce.fgov.be (Accessed: 19 January 2026).
Belgian Health Care Knowledge Center (KCE) (2024) Expenditure control measures in DRG-based hospital payment systems – Supplement. KCE Report 392S. Brussels: KCE. Available at: https://kce.fgov.be (Accessed: 19 January 2026).
INAMI-RIZIV (2019) Séjours hospitaliers pour des soins à basse variabilité: principes et modalités. Brussels: National Institute for Health and Disability Insurance. Available at: https://www.inami.fgov.be (Accessed: 19 January 2026).
INAMI-RIZIV (2025) Soins à basse variabilité – groupes APR-DRG et règles de financement. Brussels: National Institute for Health and Disability Insurance. Available at: https://www.inami.fgov.be (Accessed: 19 January 2026).
INAMI-RIZIV (2026) Mise à jour du système APR-DRG pour les soins à basse variabilité. Brussels: National Institute for Health and Disability Insurance. Available at: https://www.inami.fgov.be (Accessed: 19 January 2026).
Federal Public Service (FPS) Health, Food Chain Safety and Environment (2023) Hospital financing in Belgium: Budget des Moyens Financiers (BMF). Brussels: FPS Health. Available at: https://www.health.belgium.be (Accessed: 19 January 2026).
Busse, R., Geissler, A., Quentin, W. and Wiley, M. (2011) Diagnosis-Related Groups in Europe: Moving towards transparency, efficiency and quality in hospitals. Maidenhead: Open University Press.
OECD (2020) Pricing and payment systems for hospitals. Paris: OECD Publishing. Available at: https://www.oecd.org/health (Accessed: 19 January 2026).